ALBO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 Mar 2023 @ 05:00):

Stats
今日成交量	1.24M
平均成交量	566 901
市值	915.89M
EPS	$0 ( 2023-05-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.63
ATR14	$0.932 (2.11%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-02	Chiswell David	Sell	56 278	Common Stock
2023-03-02	Chiswell David	Sell	8 000	Stock Option (Right to Buy)
2023-03-02	Chiswell David	Sell	8 000	Stock Option (Right to Buy)
2023-03-02	Chiswell David	Sell	8 000	Stock Option (Right to Buy)
2023-03-02	Chiswell David	Sell	5 500	Stock Option (Right to Buy)

INSIDER POWER
-50.03
Last 100 transactions
Buy: 1 059 000 \| Sell: 2 762 067

音量相关性

長: 0.36 (neutral)

短: 0.10 (neutral)

Signal:(68.034) Neutral

Albireo Pharma Inc 相关性

10 最正相关
WPRT	0.988
RESN	0.98
RXDX	0.977
RETA	0.972
CSII	0.965
PATI	0.963
VREX	0.963
ZGNX	0.962
FLMN	0.961
ADMS	0.96

10 最负相关
AAON	-0.975
EYE	-0.975
THRX	-0.969
IEP	-0.962
APLS	-0.96
PINC	-0.956
PEBK	-0.956
VRAR	-0.952
NVCT	-0.948
UNAM	-0.947

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Albireo Pharma Inc 相关性 - 货币/商品

0.73
( moderate )

0.03
( neutral )

0.48
( neutral )

0.45
( neutral )

-0.75
( moderate negative )

Albireo Pharma Inc 财务报表

Annual	2021
营收:	$40.58M
毛利润:	$39.22M (96.66 %)
EPS:	$-1.770

FY	2021
营收:	$40.58M
毛利润:	$39.22M (96.66 %)
EPS:	$-1.770

FY	2020
营收:	$8.31M
毛利润:	$0.00 (0.00 %)
EPS:	$-6.73

FY	2019
营收:	$9.64M
毛利润:	$0.00 (0.00 %)
EPS:	$-5.04

Financial Reports:

No articles found.

Albireo Pharma Inc

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.